OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
WULF
TeraWulf Inc.
There isn't enough reported data to score WULF yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
WULF Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| N/A | |
| N/A |
WULF's revenue is currently healthy, but its profitability is weak. Free cash flow and net leverage aren't meaningful measures for financial services companies like WULF.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
WULF PE Valuation
WULF has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
WULF Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect WULF's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over WULF on earnings quality, reporting a profit while its opponent remains loss making.
WULF Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.30 | -$1.87 |
| Q2 2026 | -$4.40 | -$4.04 |
| Q1 2026 | -$2.51 | -$2.17 |
| Q4 2025 | -$1.66 | -$1.45 |
| Q3 2025 | -$1.43 | -$1.29 |
| Q2 2025 | -$0.36 | -$0.19 |
| Q1 2025 | -$0.34 | -$0.12 |
| Q4 2024 | -$0.21 | +$0.14 |
WULF lost $3.30 per share over the past year, a bigger loss than the year before.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over WULF on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over WULF on profitability, with a higher operating margin.
WULF Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $76.2M | +51% |
| Q2 2026 | $44.8M | -6% |
| Q1 2026 | $34M | -1.1% |
| Q4 2025 | $35.8M | +2.4% |
| Q3 2025 | $50.6M | +87% |
| Q2 2025 | $47.6M | +34% |
| Q1 2025 | $34.4M | -19% |
| Q4 2024 | $35M | +50% |
WULF's revenue is growing: $76M last quarter, up 51% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -116% | -67 points |
| Q2 2026 | -314% | -281 points |
| Q1 2026 | -477% | -303 points |
| Q4 2025 | -241% | -94 points |
| Q3 2025 | -49% | +9.3 points |
| Q2 2025 | -33% | -14 points |
| Q1 2025 | -173% | -168 points |
| Q4 2024 | -147% | -127 points |
WULF's operating margin was −116% last quarter, down 67 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over WULF on cash generation, producing positive trailing cash flow while its opponent burns cash.
WULF Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$876.9M | -$608.7M |
| Q2 2026 | -$992.3M | -$817.5M |
| Q1 2026 | -$540.5M | -$503.3M |
| Q4 2025 | -$703.2M | -$506.8M |
| Q3 2025 | -$268.3M | -$226.6M |
| Q2 2025 | -$174.8M | -$144.5M |
| Q1 2025 | -$37.2M | -$13.1M |
| Q4 2024 | -$196.4M | -$173.5M |
WULF's free cash flow was −$3.1B over the past year, against −$677M the year before. Free cash flow isn't a meaningful measure for financial services companies like WULF.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over WULF on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
WULF Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +18% | +87.9M shares |
| 1 year | +43% | +172M shares |
| 3 years | +173% | +363M shares |
| 5 years | +28923% | +572M shares |
| Available history | +28866% | +572M shares |
WULF has 574M diluted shares, up 43% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $33.3M |
| Q4 2021 | — |
WULF hasn't bought back shares in the past year.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
WULF Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2024 | -1.0x | Net Cash |
| Q2 2024 | -1.4x | Net Cash |
| Q1 2024 | 3.5x | Elevated |
| Q4 2021 | 32.9x | High |
WULF has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like WULF.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
WULF Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.6 | Neutral |
| Stochastic | 24.3 | Neutral |
WULF's weekly RSI is 41 (neutral) and its Stochastic is 24 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
WULF PE vs Financial Services Sector
| Metric | WULF | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
WULF has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over WULF on trend strength, trading above more of its moving averages.
WULF Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $13.0 | 0.2% above |
| 20 week MA | $15.9 | 18% below |
| 50 week MA | $17.1 | 24% below |
| 100 week MA | $11.9 | 9.7% above |
| 200 week MA | $7.29 | 79% above |
WULF's trend is mixed: it's above three of its five weekly moving averages, and 79% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over WULF on returns for 2026, with the stronger performance.
WULF Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.42 | $6.48 | +20% |
| 2021 | $6.48 | $14.4 | +122% |
| 2022 | $14.4 | $0.77 | -95% |
| 2023 | $0.77 | $2.40 | +212% |
| 2024 | $2.40 | $5.53 | +130% |
| 2025 | $5.53 | $11.8 | +112% |
| 2026 YTD | $11.8 | $13.0 | +11% |
WULF's yearly returns have swung widely, from +212% in 2023 to −95% in 2022. It's up 11% so far in 2026.